Clinical Trials Browser

Phase 2 × INDUSTRY × Hemostatic Disorders × Clear all

Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, Hemorrhagic Disorders, Immune System Diseases, Immunoproliferative Disorders, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Vascular Diseases, Hemostatic Disorders, Neoplasms, Plasma Cell

NCT00113802 2021-08-19

Study of Epratuzumab (hLL2) in Patients With Waldenstrom's Macroglobulinemia

Phase 2 Terminated

31 enrolled

Lymphoid

Hematologic Diseases, Lymphoproliferative Disorders, Waldenstrom Macroglobulinemia, Paraproteinemias, Hemostatic Disorders

Clinical Trials

A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.

Study of Epratuzumab (hLL2) in Patients With Waldenstrom's Macroglobulinemia